Otsuka's New Drug Application for Tolvaptan, the Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted for Review by the US Food and Drug Administration (FDA)

  • Tolvaptan was discovered by Otsuka in Japan and if approved by FDA would become the first pharmaceutical therapy for patients with ADPKD, an inherited genetic disease for which there is no current pharmaceutical treatment option
  • Otsuka's development of tolvaptan as a treatment for ADPKD illustrates the company's commitment to address untreated or undertreated diseases that have not traditionally been a priority for the pharmaceutical industry
  • ADPKD has an estimated diagnosed prevalence between 1:1,000 and 1:4,000 globally.

TOKYO--()--Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company's new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Phase III clinical trial results that form the basis of the regulatory filing were published online in the New England Journal of Medicine.1

ADPKD is a hereditary genetic illness characterized by the development of multiple cysts in the kidneys. ADPKD is the most common inherited kidney disease and the fourth most common overall cause of kidney failure worldwide, with the diagnosed prevalence estimated to be between 1:1,000 and 1:4,000 globally.

Tolvaptan is a selective V2 vasopressin receptor antagonist that has been hypothesized to slow the progression of ADPKD by reducing the development and growth of kidney cysts, which are characteristic of the disease and often associated with pain, hypertension, decreased kidney function and ultimately, kidney failure.

Under the Prescription Drug User Fee Act – or PDUFA – the FDA's goal for reviewing a drug with Priority Review status is six months from the NDA filing date. The FDA target action date (PDUFA date) for this NDA is September 1, 2013.

"The submission of this NDA represents an important milestone for Otsuka and for patients with this rare and devastating disease, and is another example of Otsuka's commitment to innovation and serving unmet medical needs," said Dr. Taro Iwamoto, President and Representative Director, Otsuka Pharmaceutical Co., Ltd. "Tolvaptan was discovered by Otsuka in Japan, and, if approved by the FDA, would become the first pharmaceutical therapy for patients who suffer from ADPKD."

About ADPKD

Autosomal Dominant (ADPKD) is characterized by the development of multiple, non-malignant cysts arising in the kidneys due to inherited or acquired genetic mutation(s).2, 3 Cyst development and growth in both kidneys leads to slow deterioration of kidney function, and in approximately 50% of patients, to end-stage renal disease (ESRD) and potential renal failure.4

ADPKD typically results in symptom manifestations (e.g. hypertension and kidney pain) in adulthood.3

About Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leading firm in the challenging area of psychiatric disorders. Tuberculosis, a global public health issue, is another research area that we have been active in for several decades. These commitments illustrate more powerfully than words how we are a "big venture" company at heart, applying a youthful spirit of creativity in everything we do.

Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. Our chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD 14.7 billion for fiscal year 2011 (4/1/2011-3/31/2012.) We welcome you to visit our global website at https://www.otsuka.co.jp/en/

 
1 Article published on November 3rd, 2012 at NEJM.org
2 Torres, VE, Harris, PC, and Pirson, Y. Autosomal Dominant Polycystic Kidney Disease Lancet. 2007;369:1287-1301.
3 Tan Y, Blumenfeld J, and Rennert H. Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs. Biochimica Biophysica Acta. 2011;1812:1202-1212.
4 Patel V, Chowhury R, and Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009;18:99-106.

Contacts

U.S.
Otsuka America Pharmaceutical, Inc.
Rose Weldon, +1 609 524 6879/+1 215 801 7644 (cell)
rose.weldon@otsuka-us.com
or
JAPAN/ASIA
Otsuka Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81-3-6361-7379/+81-80-2066-7289
gilbert.jeffrey@otsuka.jp
or
EUROPE
Otsuka Pharmaceutical Europe, Ltd.
Alison Ross, +44 7768337128 (cell)
ARoss@Otsuka-Europe.com
or
INVESTOR INQUIRIES
Otsuka Holdings Co., Ltd.
Takuma Kimura, +81-3-6361-7411/+81-90-9010-7194
kimura@otsuka.jp

Sharing

Contacts

U.S.
Otsuka America Pharmaceutical, Inc.
Rose Weldon, +1 609 524 6879/+1 215 801 7644 (cell)
rose.weldon@otsuka-us.com
or
JAPAN/ASIA
Otsuka Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81-3-6361-7379/+81-80-2066-7289
gilbert.jeffrey@otsuka.jp
or
EUROPE
Otsuka Pharmaceutical Europe, Ltd.
Alison Ross, +44 7768337128 (cell)
ARoss@Otsuka-Europe.com
or
INVESTOR INQUIRIES
Otsuka Holdings Co., Ltd.
Takuma Kimura, +81-3-6361-7411/+81-90-9010-7194
kimura@otsuka.jp